tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Scilex Evaluates Strategic Options for Semnur Pharmaceuticals

Scilex Evaluates Strategic Options for Semnur Pharmaceuticals

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Scilex Holding Company (SCLX) has provided an announcement.

Scilex Holding Company is considering a strategic move to boost the value of its subsidiary, Semnur Pharmaceuticals, and its product candidate, SEMDEXA™. The Board of Directors has given the green light to investigate various options, such as a spin-off, merger, or other transactions, with the goal of enhancing stockholder returns. This initiative represents a proactive approach to capitalize on the subsidiary’s assets and potential.

See more insights into SCLX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1